Among patients restarting subcutaneous infliximab, prior ADA positivity was reported in 72.5% of patients with Crohn's disease and 92.2% of those with ulcerative colitis. The median interval between ...
In both analyses, aprocitentan produced rapid, double-digit reductions in blood pressure. The treatment was also associated with improvements in urinary albumin-to-creatinine ration (UACR), a marker ...
European stocks traded higher on Monday, after having recovered from four-month lows in the previous session on U.S. President Trump's remarks dismissing speculation of pre-midterm military action ...
European stocks traded higher on Monday, after having recovered from four-month lows in the previous session on U.S. President Trump's remarks dismissing speculation of pre-midterm military action ...
Asian stocks turned in a mixed performance on Monday, with South Korean markets falling sharply due to worsening investor sentiment in the semiconductor sector on growing concerns over the AI industry ...
Integra LifeSciences Holdings Corp. ( IART ), a global medical technology company, announced the pricing of $450 million aggregate principal amount of 9.5% senior secured notes due 2033.
First Tracks Biotherapeutics, Inc. , a clinical-stage biotechnology company, is set to review top-line data from the Cohort 1 Phase 1b trial of ANB033 in celiac disease during an ...
Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to opamtistomig (LBL-024), its investigational antibody, for the ...
Denmark's consumer price inflation accelerated to a one-year high in September, driven by rising energy prices, data published by Statistics Denmark showed Monday. Consumer prices rose 2.2 percent ...
Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing ...
Freenome, Inc. ( FRNM ), a company that develops blood tests for early cancer detection, announced it will present late-breaking data on an updated version of its SimpleScreen CRC blood-based ...
The Phase 3 CALIBRATE trial evaluated encaleret against standard care (SoC), consisting of calcium supplements and/or active vitamin D, in patients with ADH1. The newly presented findings covered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results